Novo Nordisk has announced that it will present 34 abstracts on its portfolio at the 84th Scientific Sessions of the American Diabetes Association (ADA), to be held June 21-24, 2024 in Orlando.

Among the presentations, additional data from three major semaglutide trials will be highlighted.

These trials are evaluating the potential benefits of semaglutide for people with type 2 diabetes and chronic kidney disease (FLOW), as well as obese people with cardiovascular disease (SELECT and STEP HFpEF).

Stephen Gough, Senior Vice President and Global Medical Director of Novo Nordisk, emphasized the importance of developing drugs that treat the multiple facets of interconnected cardiometabolic diseases such as cardiovascular disease, chronic kidney disease, obesity and type 2 diabetes.

Abstracts will be published on the Diabetes journal website, and session data will be available after presentation.

Copyright (c) 2024 All rights reserved.